Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE ...

A low-dose (40 mg) modified formulation of minocycline hydrochloride (DFD-29) was better tolerated and more effective than doxycycline and placebo in patients with moderate to severe ...

Division of Biomedical Sciences, University of California Riverside, California, USA Dr D Ethell, Biomedical Sciences, University of California, 900 University Ave, Riverside, CA 92521-0121, USA; doug ...

ABSTRACT: Confluent and reticulated papillomatosis (CARP) is a chronic dermatologic condition marked by hyperpigmented, verrucous papules and plaques that merge into a characteristic net-like, ...

SCOTTSDALE, Ariz. - Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company valued at $106 million, announced the publication of positive results from two Phase 3 ...